Asterias Biotherapeutics (AST) Reports Update on AST-OPC1 Phase 1/2a Clinical Trial
Tweet Send to a Friend
Asterias Biotherapeutics, Inc. (NYSE: AST) today provided additional data from the company’s ongoing Phase 1/2a SCiStar study designed to evaluate ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
